The article recommends three undervalued growth stocks for investors with $2,000 to deploy: Shopify, which has declined 40% but remains the future of e-commerce; Nice Ltd, a customer service automation specialist with strong AI integration potential; and Viking Therapeutics, an emerging weight-loss drug developer with a potentially superior GLP-1 alternative in phase 3 trials.

President Trump's Q1 2026 financial disclosures revealed significant purchases of Eli Lilly stock, a major player in the booming anti-obesity drug market. The article cautions investors against simply copying political trades, emphasizing that investment decisions should be based on business fundamentals rather than celebrity or political endorsements. Eli Lilly's obesity treatments Mounjaro and Zepbound generated over $30 billion in combined sales in 2025, with analysts projecting the global anti-obesity drug market could exceed $95-200 billion. While Lilly maintains a strong competitive position with manufacturing advantages and a robust pipeline, its premium valuation already reflects years of future growth, presenting significant downside risk if sales slow or competition intensifies.

The obesity drug market is projected to reach nearly $100 billion by decade's end. While Eli Lilly and Novo Nordisk dominate, two other companies—Viking Therapeutics and AbbVie—are positioned for significant growth. Viking is advancing VK-2735, a dual GLP-1/GIP receptor agonist in phase 3 trials with promising results. AbbVie is developing ABBV-295, a long-acting amylin analog with positive phase 1 data. Both stocks are predicted to potentially double in 2026 based on upcoming trial results and market expansion.

Eli Lilly achieved a significant phase 3 trial win with retatrutide, a weight loss drug candidate that demonstrated superior efficacy compared to current market leaders. The drug helped patients lose an average of 28% of body weight over 80 weeks by acting on three hormonal pathways, compared to Novo Nordisk's single-pathway and Lilly's existing dual-pathway drugs. With 60% U.S. market share and this promising new candidate, Lilly is positioned to maintain dominance in the rapidly growing weight loss drug market expected to reach $100 billion by the early 2030s.

Viking Therapeutics is increasingly viewed as an acquisition target for large pharmaceutical companies seeking obesity drug exposure. The company's lead candidate VK2735 shows strong efficacy data in both injectable and oral formulations, with Phase 3 trials underway. With a market cap of $3.6B and $603M in cash, Viking trades at $30/share while analysts project $95 price targets, making it potentially cheaper for big pharma to acquire than develop competing assets independently.

Abivax and Viking Therapeutics are two biotech companies that could potentially double in value by 2030 if their leading drug candidates succeed in clinical trials and regulatory approval. Abivax is developing obefazimod for ulcerative colitis, while Viking Therapeutics is advancing VK2735 for weight loss treatment. Both stocks carry significant risk due to their clinical-stage status and lack of approved products.

Viking Therapeutics announced its participation in two major investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference (June 2-4 in Chicago) and the Jefferies Global Healthcare Conference (June 3-4 in New York). The clinical-stage biopharmaceutical company will present its pipeline including VK2735 for obesity, VK2809 for metabolic disorders, and VK0214 for rare disease treatment.

The GLP-1 weight-loss drug market is booming with three main investment options. Eli Lilly leads with strong Mounjaro and Zepbound sales growth but trades at an expensive 35x P/E ratio. Novo Nordisk, the first-to-market player, faces pricing pressures and patent expirations but offers a compelling turnaround opportunity at a 10x P/E after a 45% stock decline. Viking Therapeutics represents a high-risk, high-reward bet for aggressive investors with GLP-1 drugs in clinical trials.

Eli Lilly's stock has surged above $1,000 following strong Q1 results driven by its dominance in weight-loss and diabetes markets. Despite increasing competition from rivals like Novo Nordisk and Amgen, the company maintains advantages through superior pipeline candidates like Retatrutide and diversified revenue streams in oncology, immunology, and neuroscience. AI-powered drug development efforts could further accelerate growth, potentially enabling the stock to double within six years.

Eli Lilly dominates the rapidly growing weight loss drug market with its GLP-1 drugs Mounjaro and Zepbound, generating over $12 billion in quarterly sales. The company recently launched Foundayo, an oral GLP-1 pill, which could cannibalize Zepbound sales but is more likely to expand the patient base by attracting new GLP-1 users. While Lilly faces competition from Novo Nordisk and other pharma companies, analysts view Foundayo as a growth opportunity rather than a threat.

U.S. stocks fell Monday as an Iranian drone strike on a UAE oil facility sent Brent crude above $114 a barrel, raising inflation concerns and expectations of a potential Fed rate hike by March 2027. The S&P 500 dropped 0.5%, the Dow fell 1.0%, and the Nasdaq 100 declined 0.7%. Energy stocks rallied while transportation, logistics, and rate-sensitive sectors suffered significant losses. Defense stocks gained on Pentagon spending narratives, while software and crypto-related equities found strength.

Eli Lilly announced strong growth in its weight loss drug portfolio, with Mounjaro revenue up 125% to $8.6B and Zepbound up 80% to $4.1B. The company's new oral weight loss drug Foundayo launched last month and has already reached 20,000 patients, with 80% being new to GLP-1 drugs. Foundayo offers advantages over competitors, including no food restrictions unlike Novo's oral Wegovy, positioning Lilly to continue gaining market share in the rapidly growing weight loss drug market.